Date: 2017-02-17
Type of information: Results
phase: 3
Announcement: results
Company: ArQule (USA - MA) Daiichi Sankyo (Japon)
Product: tivantinib (ARQ 197)
Action mechanism: tyrosine kinase inhibitor. Tivantinib is an orally administered, selective inhibitor of MET, a receptor tyrosine kinase. Tivantinib is currently in Phase 3 development and has not yet been approved in any market. In healthy adult cells, MET is present in normal levels to support natural cellular function, but in cancer cells MET is inappropriately and continuously activated for unknown reasons. When abnormally activated, MET plays multiple roles in aspects of human cancer, including cancer cell growth, survival, angiogenesis, invasion and metastasis. In December 2008 , ArQule and Daiichi Sankyo signed a license, co-development and co-commercialization agreement for tivantinib in the U.S. , Europe , South America and the rest of the world, excluding Japan , China (including Hong Kong ), South Korea and Taiwan . In November 2015 , ArQule exercised its co-commercialization option for tivantinib in the U.S. A co-commercialization agreement is expected to be finalized in the first quarter of 2016.
Disease: hepatocellular carcinoma
Therapeutic area: Cancer - Oncology
Country: Argentina, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Italy, Netherlands, New Zealand, Portugal, Spain, Sweden, Switzerland, USA
Trial details: METIV-HCC is a biomarker-selected, double-blind, placebo-controlled, randomized phase 3 study evaluating tivantinib (2:1) versus best supportive care in patients with MET-overexpressing, inoperable hepatocellular carcinoma intolerant to or previously-treated with systemic therapy. A total of 340 patients with MET overexpressing hepatocellular carcinoma analyzed by a validated immunohistochemical assay were randomized in the intent to-treat population for efficacy analysis. The primary endpoint of the study is overall survival. Secondary endpoints include progression-free survival and safety. (NCT01755767)
Latest
news:
The METIV-HCC trial, being conducted in western countries in partnership with Daiichi Sankyo, has completed enrollment and a planned interim analysis, which is triggered when 60% of events occur, is expected to take place early in the second quarter of 2016. The trial enrolled over 300 patients, is randomized 2:1 treatment to best supportive care, and has overall survival as its primary end-point.